Small cell lung cancer (SCLC) cells are missing a surface protein that triggers an immune response, allowing them to hide from one of the body's key cancer defenses, a new study led by UT Southwestern researchers suggests. ...
20 hours ago
0
40
Researchers from The University of Texas MD Anderson Cancer Center have developed the first comprehensive framework to classify small-cell lung cancer (SCLC) into four unique subtypes, based on gene expression, and have identified ...
Jan 21, 2021
0
10
Overall cancer death rates in the United States dropped continuously from 1991 through 2018 for a total decrease of 31%, including a 2.4% decline from 2017 to 2018. The news comes from the American Cancer Society's annual ...
Jan 12, 2021
0
5
Researchers at the Children's Medical Center Research Institute at UT Southwestern (CRI) have discovered a new metabolic vulnerability in a highly aggressive form of non-small cell lung cancer (NSCLC). These findings could ...
Jan 05, 2021
0
46
Michael Green, M.D., Ph.D., noticed that when his patients had cancer that spread to the liver, they fared poorly—more so than when cancer spread to other parts of the body. Not only that, but transformative immunotherapy ...
Jan 04, 2021
0
156
Tagrisso (osimertinib) received approval as an adjuvant treatment for patients with non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, the U.S. Food and Drug ...
Dec 23, 2020
0
4
Scientists have long known that therapies that target the cancer-driving MAPK pathway are only effective in a handful of cancers with specific mutations in a cancer gene called BRAF, and these cancers that initially respond ...
Dec 14, 2020
0
78
The results of a large, retrospective study of patients who received a form of immunotherapy for non-small cell lung cancer (NSCLC) revealed that patients may get more than one immune-related side effect, and identified a ...
Dec 14, 2020
0
6
Lung cancer patients with a specific genetic alteration lived longer and were protected against metastasis to the brain when treated early with the drug lorlatinib (Lorbrena), according to a study led by researchers at Massachusetts ...
Nov 18, 2020
0
20
Scientists are beginning to unravel one of the biggest challenges with immunotherapy: why some people with cancer respond to the treatment, while others may not respond at all.
Nov 16, 2020
0
108
